CareLit Fachartikel

Cardiovascular safety of liraglutide: Pooled analysis of Major adverse cardiovascular events across weight management and Type 2 Diabetes development programs

S Jacob, T Wehrhahn, I Caterson, S Bain, J Gross, J House, A Salisbury, S Marso, F Baeres, M Donsmark · Diabetologie und Stoffwechsel · 2016 · Heft 04

Dokument
987676
CareLit-ID
Jahr
2016
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Diabetologie und Stoffwechsel
Autor:innen
S Jacob, T Wehrhahn, I Caterson, S Bain, J Gross, J House, A Salisbury, S Marso, F Baeres, M Donsmark
Ausgabe
Heft 04 / 2016
Seiten
–
Erschienen: 2016-04-19 00:00:00
ISSN
1861-9002
DOI
10.1055/s-0036-1580943

Zusammenfassung

A meta-analysis of five phase II/III liraglutide (up to 3.0 mg) weight management (WM) trials, additional sensitivity meta-analyses of 21 liraglutide type 2 diabetes (T2D) trials (up to 1.8 mg) and a pre-specified pooled analysis of WM+T2D trials (n = 27) were performed to assess liraglutide's cardiovascular safety in individuals with overweight/obesity and T2D. The primary endpoint was first occurrence of adjudicated major adverse cardiovascular events (MACE) (non-fatal myocardial infarction, non-fatal stroke, cardiovascular death) with liraglutide (any dose) or pooled total comparator (placebo, active) using a…

Schlagworte

Diabetologie und Stoffwechsel